In episode #7 of Future of Drug Discovery by Murat Tunaboylu (Antiverse), Alan Nafiiev, CEO and Co-Founder of Receptor.AI, discusses how AI is reshaping early-stage drug discovery. He shares the company’s evolution, key technological milestones, and how their AI-driven SaaS platform supports pharma and biotech teams in designing small molecules against challenging targets. Alan also outlines Receptor.AI’s direction for 2023, including its work in membranotropic drug discovery for oncology and cardiovascular diseases.

🔗 Listen to the full episode — Alan Nafiiev – Receptor AI – Membranotropic Drug Discovery (FODD #7)